Comparative Pharmacology
Head-to-head clinical analysis: MELLARIL versus SPARINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELLARIL versus SPARINE.
MELLARIL vs SPARINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thioridazine is a phenothiazine antipsychotic that blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors, and also blocks alpha-adrenergic receptors, histamine H1 receptors, and muscarinic M1 receptors.
Phenothiazine antipsychotic; blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors; also blocks alpha-adrenergic receptors, and has anticholinergic and antihistaminergic effects.
Typical adult dose: 10-25 mg orally 3 times daily. Maximum dose: 200 mg/day.
Promazine hydrochloride: 25-50 mg intramuscularly or intravenously every 4-6 hours as needed; maximum 300 mg/day. Alternatively, oral: 25-200 mg every 4-6 hours; maximum 1000 mg/day. Route and frequency depend on indication and patient response.
None Documented
None Documented
Terminal elimination half-life 21-24 hours; steady-state achieved within 5-7 days
Terminal elimination half-life: 10-20 hours; clinical context: allows once or twice daily dosing; extended in elderly and hepatic impairment
Primarily renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Primarily renal (70-80% as metabolites, less than 1% unchanged); biliary/fecal (15-30%)
Category C
Category C
Antipsychotic
Antipsychotic